Multicenter, prospective study using the novel predictive factor of the anti PD-1 antibody for urological cancers (renal cell carcinoma, urothelial cancer)
- Conditions
- renal cell carcinoma urothelial cancer
- Registration Number
- JPRN-UMIN000033039
- Lead Sponsor
- Kindai University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- All
- Target Recruitment
- 80
Not provided
1)A synchronism overlap cancer or the patient whom a disease-free period has heterochrony overlap cancer within five years *But I do not do Carcinoma in situ (cancer in the epithelium) and the intramucosal carcinoma judged that I was cured by local treatment with the exclusion. 2)The patient whom I am complicated with mental disease or a mind symptom, and it is judged to have difficulty in participation in study 3)The patient who gives it from head to foot of steroids more than four weeks *But I permit it to the steroid within 10 mg/day by prednisolone conversion. 4)in addition, the patient that a study responsibility doctor or an allotment doctor judged the participation in this study to be inappropriate
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Association between disease control rate and PBMC biomarker
- Secondary Outcome Measures
Name Time Method ORR Objective Response Rate TTF Time to Treatment Failure PFS Progression Free Survival OS Overall Survival safety and tolerability Comparison of the DCR, ORR PFS OS with non effective patient
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.